Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
BPC-157 Arginate vs Larazotide
An educational, source-based comparison of BPC-157 Arginate and Larazotide — how each peptide works, what it's researched for, and what to know before going deeper.
Stabilized salt form of BPC-157 with enhanced stability.
An arginate salt formulation of BPC-157 designed to improve stability and shelf-life. Research suggests the same angiogenic, anti-inflammatory, and tissue-repair mechanisms as standard BPC-157, with potentially improved bioavailability.
- Tendon and ligament healing
- Gastric ulcer protection
- Neuroprotection and nerve repair
- Systemic anti-inflammatory effects
- • Same cautions as standard BPC-157: preclinical data, not FDA-approved.
- • Quality of compounded formulations varies widely.
An octapeptide zonulin antagonist that helps maintain intestinal tight junction integrity, reducing paracellular permeability triggered by gluten in celiac disease.
- Celiac disease (Phase 3 completed)
- Intestinal barrier function ('leaky gut' research)
- Environmental enteropathy
- • Not yet FDA-approved.
- • Investigational; physician oversight required.
BPC-157 Arginate vs Larazotide — Key differences
- Class: BPC-157 Arginate is classified as Tissue Repair · Gastrointestinal, while Larazotide is Gastrointestinal · Barrier.
- Primary research focus: BPC-157 Arginate — tendon and ligament healing; Larazotide — celiac disease (phase 3 completed).
- Tag: Recovery vs Gut.